Note: Ingredients listed on restricted chemical lists
EC/CAS
232-274-4/8001-22-7
Name of the chemical
soybean oil
Concentration
N/A
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
85-86
General Information
Version
1.0
Revision date
2015-06-29
Product name
PropoFlo
Product Synonyms
PropoFlo Single Dose Vial; Propofol ES; Propofol Injectable Emulsion 10 mg/mL
Chemical name
Mixture
1.2.1 Relevant identified uses
Veterinary anesthetic agent
Emergency telephone
1-800-424-9300, +1-703-527-3887
Icons in SDS
Company Information
company name
Zoetis Inc
e-mail address of the competent person responsible for the Safety Data Sheet
VMIPSrecords@zoetis.com
GHS Information
Signal word
Not Classified
Section 2
SECTION 2: Hazards identification
Appearance White to off-white aqueous emulsion Classification of the Substance or Mixture GHS - Classification Not classified as hazardous EU Classification EU Indication of danger Not classified
Signal word
Not Classified
Hazard statements
Non-hazardous in accordance with international standards for workplace safety.
2.3 Other hazards
Short Term Expected to have a low hazard potential based on available information. Rare cases of self- injection have been reported to cause death. May cause eye, skin and respiratory tract irritation . Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. Signs and symptoms might include skin rash, itching, redness or swelling. Respiratory reactions may be characterized by rhinitis, sneezing, scratchy throat, oral mucosal edema, laryngeal mucosal edema, coughing, shortness of breath, wheezing, and chest pain. Asthma like reactions occur with acute exposures in sensitized patients. May be absorbed through mucous membranes and cause systemic effects. Vapors may cause drowsiness and dizziness. Breathing high vapor concentrations may cause central nervous system (CNS) depression resulting in dizziness, light-headedness, headache, nausea, and loss of coordination. Continued inhalation may result in unconsciousness and death. Known Clinical Effects Known Clinical Effects: decreased heart rate (bradycardia) , decrease in blood pressure (hypotension) , nausea , vomiting , sedation , sleepiness (somnolence) , anaphylactic reactions , respiratory depression , CNS depression , unconsciousness , drowsiness, dizziness, abnormal thinking, euphoria, headache, and incoordination. Australian Hazard Classification (NOHSC): Note Non-Hazardous Substance. Non-Dangerous Goods. This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
2.1 Classification of the substance or mixture
EU Classification: EU Indication of danger: Not classified Label Elements
